← Back to Clinical Trials
Recruiting NCT07389538

NCT07389538 Promoting Safe Medication Practices in the Classroom

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07389538
Status Recruiting
Phase —
Sponsor Universidad de Granada
Condition Self Medication
Study Type INTERVENTIONAL
Enrollment 202 participants
Start Date 2025-03-17
Primary Completion 2026-11

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age 24 Years
Study Type INTERVENTIONAL
Interventions
Educational intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 202 participants in total. It began in 2025-03-17 with a primary completion date of 2026-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Self-medication has traditionally been defined as the consumption of medicines, herbs, and home remedies on one's own initiative or on the advice of another person, without consulting a doctor. In Spain, the consumption of non-prescription drugs is quite widespread among young people, since more than half of them have used medications without a medical prescription in the last year. This high prevalence of self-medication among Spanish youth seems to be driven by various factors that encourage this practice. These include the increase in over-the-counter medications, delays in obtaining appointments at health centers, the influence of common family self-care practices, and the population's greater knowledge of and interest in health-related issues. Inappropriate use of medications constitutes a public health problem and can cause significant risks to users' health, such as adverse reactions, drug resistance, and complications in diagnosing diseases, since it can lead to the masking of symptoms, as well as an increase in morbidity. However, not all self-medication practices are harmful. Responsible self-medication refers to the use of over-the-counter medications (without a prescription) to treat common and mild symptoms (e.g., fever, mild pain, colds) for a reasonable period of time (two to three days, after which a doctor should be consulted if no improvement occurs). The benefits of responsible self-medication include convenience for the patient, reinforcement of personal autonomy through self-care, reduction of healthcare professionals' workload, and decreased costs to the healthcare system. In this regard, responsible self-medication not only provides individual and collective benefits but also promotes the development of personal autonomy, a key factor influencing young people's tendency to self-medicate. Attitudes toward autonomous medication use in young people are influenced by individual variables such as emotional regulation, family habits, peer influence, quality of life, and the use of other substances. Given that these factors-greater access to medications, delays in healthcare access, family self-care practices, and individual psychosocial characteristics-appear to drive self-medication behaviors among youth, it is hypothesized that an educational intervention developed with the support of artificial intelligence, and focused on the responsible and safe use of medications, will improve young people's knowledge and attitudes toward self-medication. By targeting both knowledge and attitudes, the intervention aims to strengthen responsible practices while fostering autonomy and informed decision-making in medication use.

Eligibility Criteria

Inclusion Criteria: * Inclusion criteria will include being a student at secondary education institutions, vocational training programs, or undergraduate degree programs in the province of Granada, and being between 15 and 24 years of age. Exclusion Criteria: * Exclusion criteria will include: lack of informed consent from the participant or their legal guardians in the case of minors, and the presence of barriers that prevent proper understanding of the questionnaires and activities to be carried out (e.g., language barriers, intellectual disability, etc.).

Contact & Investigator

Central Contact

María Correa-Rodríguez, PhD

✉ macoro@ugr.es

📞 +34958243494

Principal Investigator

María Correa-Rodríguez, PhD

PRINCIPAL INVESTIGATOR

Universidad de Granada

Frequently Asked Questions

Who can join the NCT07389538 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, up to 24 Years, studying Self Medication. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07389538 currently recruiting?

Yes, NCT07389538 is actively recruiting participants. Contact the research team at macoro@ugr.es for enrollment information.

Where is the NCT07389538 trial being conducted?

This trial is being conducted at Granada, Spain.

Who is sponsoring the NCT07389538 clinical trial?

NCT07389538 is sponsored by Universidad de Granada. The principal investigator is María Correa-Rodríguez, PhD at Universidad de Granada. The trial plans to enroll 202 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology